Precision Medicine Day Two


Precision 2018 Day 2

08:00 Registration opens

Opening keynotes: Precision medicine stories


Chair's opening remarks

Paul Peter Tak

Towards prevention of autoimmune disease: the example of rheumatoid arthritis

  • Predictors for rheumatoid arthritis (RA) development will be presented
  • PRAIRI study is the first evaluating the effects of a biopharmaceutical in subjects at risk of developing RA
  • A single infusion of 1000 mg rituximab delays the development of arthritis up to 12 months
Paul Peter Tak

Stories from AstraZeneca’s innovative medicines and early development biotech unit

  • Quality, not quantity: Improving productivity by implementation of a company-wide framework and a precision approach
  • A success story of precision medicine in oncology and moving into other therapy areas – identifying the right target, in the right patients, at the right time for the best outcome to improve patients’ lives
  • Identifying new drug targets following a genomic approach across all therapy areas
Kari Stefansson

From discovery genetics to precision medicine


Reserved for supporting partner

Please contact Erica Baeta (+44 (0)207 092 1152, or Derek Cavanagh (+44 (0)207 092 1297, for further details

10:40 Networking Break

round tables

Roundtable discussion session

This roundtable session will run as two, 30 minute rotations, enabling you to join 2 roundtables of your choice
Table 1: Health economics meets real world data
Table 2: Ethics to consider when discussing precision medicine
Table 4: Cost and benefits of precision medicine
Alastair Kent OBE

Alastair Kent OBE, Ambassador, Genetic Alliance U.K.

Table 6: Diagnostics – where precision medicine will take us
Table 7: Whole body screening – the future of healthcare
Table 8: Precision medicine for infectious disease

Speed Networking

A fun, exciting and effective way to make a lot of initial connections (in a very different environment from the standard business networking meetings)
Panel discussion

13:00 Networking Lunch

Break out panel: Patient involvement in precision medicine
  • What are the benefits of involving the public in precision medicine
  • The patient experience with precision medicine and patient involvement
  • How clinicians can improve the patient experience
  • What are the barriers to involvement and how can they be overcome

Drug development

Precision Medicine - Oncology

Precision Medicine - Oncology

Chaired by TBC

Precision Medicine - Oncology

Mendelian genomics and precision medicine efforts at Yale

  • Biomarker discovery for Mendelian and Cancer Genomics
  • Precision Medicine initiative/efforts at Yale
  • Present PM cases of liver and brain cancer
  • Impact of new and upcoming technologies on PM
Drug Development

Leveraging known causal human biology for discovering new drugs for orphan diseases

  • In many cases the underlying cause of orphan diseases is known, often being genetic nature
  • However, that the trajectory of disease causing events and a validated therapeutic intervention point are also known does not necessarily follow
  • I will discuss the key requirements and approaches for addressing diseases where the essential causative events are known as well outline how this should differ for diseases where this is not the case
Stuart Hughes, Director and Head of Pharmacology, Vertex Pharmaceuticals
Precision Medicine - Oncology

The Human Protein Atlas - implications for human biology and precision medicine

  • Knowledge of the spatial distribution of proteins is essential to understand human biology in health and disease
  • The Human Protein Atlas constitutes an open-access knowledge-based resource, focusing on an integrated omics approach for in situ detection of human proteins down to the single cell level
  • All human protein coding genes have been classified using a combination of genomics, transcriptomics, proteomics and antibody-based profiling, and used for studying global protein expression patterns
Drug Development

The evolution of Pharmacogenetics (PGx) as a tool to support drug development

  • What have we learned about PGx over the last 10 years
  • How best can we utilise this to support drug development going forward
  • The utility of clinical trials and PGx to support target validation
Precision Medicine - Oncology

CRUK Stratified Medicine Programme: Experiences of delivering a national precision medicine initiative

  • Overview and update of CRUK’s Stratified Medicine Programmes and National Lung Matrix Trial
  • Challenges faced in delivering a Precision Medicine initiative
  • How SMP2 has approached addressing some of these challenges
  • Next steps for SMP2 and Precision Medicine Initiatives
Sumi Subramaniam, Programme Manager, Precision Medicine, Research & Innovation, Cancer Research UK
Drug Development

Implementing precision medicines: what are the challenges?

  • Sharing of case-studies/examples on challenges and solutions in precision medicine development through to integration in treatment pathways, including;
  • Biomarker discovery
  • Clinical trial design and delivery
  • Drug-diagnostic co-development
  • Precision Medicine launch and delivery to the patient
Precision Medicine - Oncology

Precision medicine in oncology: what is it exactly and where are we?

  • A better understanding of cancer biology has opened the door of precision medicine in oncology
  • The identification of specific molecular alterations in some tumour types has translated into major therapeutic achievements
  • High throughput technologies have allowed the elaboration of prognostic signatures that led to treatment de-intensification in breast cancer
  • However, it has not been demonstrated to date that the use of high throughput technologies to guide therapy improved patients’ outcomes
Vivienne Parry

15:50 Networking break

Breakout Panel: Inside the ethics committee – the ethics behind using precision medicine
  • Panel exploring the various ethical implications surrounding precision medicine
  • Big data and patient data usage
  • Best practice for ethical decisions

Precision Medicine - Rare Disease

Drug development

Drug Development

Major public-private biomedical research partnership managed by the Foundation for the National Institute of Health

Reserved for supporting partner
Please contact Erica Baeta (+44 (0)207 092 1152, or Derek Cavanagh (+44 (0)207 092 1297, for further details
Precision Medicine - Rare Disease

Precision and recall oncology: combining multiple gene mutations for improved identification of drug-sensitive tumours

  • There is a need for new methods able to better discriminate between sensitive and resistant tumours to a given cancer treatment from the genomic profiles of these tumours
  • Combining multiple gene mutations via machine learning results in better discrimination than that provided by the best single-gene marker in about half of the 127 analysed drugs
  • Importantly, the proportion of sensitive cell lines that are correctly predicted as sensitive (recall) of the single-gene marker was lower than that of the multi-gene marker in 93% of the drugs
Healthcare Track

What does good care feel like? A patient's perspective

  • What do we mean by precision medicine? 
  • Expectations, fears and hope
  • Precision - in care, treatment and communication
Drug Development

Genomic scale drug design

  • First time in history we can have full genome binding affinity for molecules
  • This will shift the industry to a different design process, less risky, more precise
  • Opening of the single genome drug optimisation
Drug Development

A community assessment of cancer drug combination screens identifies strategies for synergy prediction

  • Crowd-sourced advancement of computational drug synergy predictions
  • Meta-analysis of one of the largest participated DREAM challenges so far
  • Identification of drug response biomarkers
Michael Menden, Senior Scientist, AstraZeneca
Precision Medicine - Rare Disease

Need for patient registries for rare disease clinical trials and how to integrate them into the EMR

  • Hear how Sanford Research built a registry for batten disease and how they are expanding it and implementing it into electronic health records
  • What do these registries mean for clinical trials in the rare disease field?
  • How do approaches to registries and electronic health systems differ globally?
Drug Development

Academic built compounds (ABC) – with the move to drug discovery platforms are we forgetting our ABCs?

  • An overview of the Oncology drug development landscape - comparing approaches and exhibiting the successes from Academia
  • MicroQuin is offering a novel approach and first-in-class treatment to ALL Breast Cancers.  This will spotlight MicroQuin’s efforts and explain why this can’t be found using a platform approach
  • Examining the Oncology pipeline: The next generation drugs and why ABC is still unbeatable
Precision Medicine - Rare Disease

The bio-inspired artificial pancreas for treatment of diabetes in the home

  • Microchip technology can create systems inspired by biology to provide control of disease
  • The Bio-inspired Artificial Pancreas has been developed and clinically validated in people with diabetes
  • Our device can improve glucose control and reduce hypoglycaemia
  • This improves quality of life in subjects with diabetes and reduces secondary complications

17:50 End of day 2: Poster viewing and networking drinks reception

last published: 16/Mar/18 13:45 GMT




Sign Up for Event Updates

World Precision Medicine Congress


Erica Baeta
+44 (0)207 092 1152


Joan Shutt
t/ +44 (0)207 092 1134


Issa Mauthoor
+44 (0)207 092 1257